Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate ...
Martin Ford We can't close our eyes to the the risks and the dangers that come with this technology, right? And I really ...
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
University of Colorado Boulder is introducing a new Master's and portfolio program that promises to better train junior employees because agencies and marketers are falling short.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback